Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 378

1.

Targeted next-generation sequencing identifies clinically relevant somatic mutations in a large cohort of inflammatory breast cancer.

Liang X, Vacher S, Boulai A, Bernard V, Baulande S, Bohec M, Bièche I, Lerebours F, Callens C.

Breast Cancer Res. 2018 Aug 7;20(1):88. doi: 10.1186/s13058-018-1007-x.

2.

Medullary Breast Carcinoma, a Triple-Negative Breast Cancer Associated with BCLG Overexpression.

Romero P, Benhamo V, Deniziaut G, Fuhrmann L, Berger F, Manié E, Bhalshankar J, Vacher S, Laurent C, Marangoni E, Gruel N, MacGrogan G, Rouzier R, Delattre O, Popova T, Reyal F, Stern MH, Stoppa-Lyonnet D, Marchiò C, Bièche I, Vincent-Salomon A.

Am J Pathol. 2018 Jul 31. pii: S0002-9440(17)31226-9. doi: 10.1016/j.ajpath.2018.06.021. [Epub ahead of print]

PMID:
30075151
3.

Coronin 1C promotes triple-negative breast cancer invasiveness through regulation of MT1-MMP traffic and invadopodia function.

Castagnino A, Castro-Castro A, Irondelle M, Guichard A, Lodillinsky C, Fuhrmann L, Vacher S, Agüera-González S, Zagryazhskaya-Masson A, Romao M, El Kesrouani C, Noegel AA, Dubois T, Raposo G, Bear JE, Clemen CS, Vincent-Salomon A, Bièche I, Chavrier P.

Oncogene. 2018 Jul 31. doi: 10.1038/s41388-018-0422-x. [Epub ahead of print]

PMID:
30065298
4.

Prognostic impact of residual HPV ctDNA detection after chemoradiotherapy for anal squamous cell carcinoma.

Cabel L, Jeannot E, Bièche I, Vacher S, Callens C, Bazire L, Morel A, Bernard-Tessier A, Chemlali W, Schnitzler A, Lièvre A, Otz J, Minsat M, Vincent-Salomon A, Pierga JY, Buecher B, Mariani P, Proudhon C, Bidard FC, Cacheux W.

Clin Cancer Res. 2018 Jul 27. pii: clincanres.0922.2018. doi: 10.1158/1078-0432.CCR-18-0922. [Epub ahead of print]

PMID:
30054279
5.

Inhibition of mTOR downregulates expression of DNA repair proteins and is highly efficient against BRCA2-mutated breast cancer in combination to PARP inhibition.

El Botty R, Coussy F, Hatem R, Assayag F, Chateau-Joubert S, Servely JL, Leboucher S, Fouillade C, Vacher S, Ouine B, Cartier A, de Koning L, Cottu P, Bièche I, Marangoni E.

Oncotarget. 2018 Jul 3;9(51):29587-29600. doi: 10.18632/oncotarget.25640. eCollection 2018 Jul 3.

6.

ETV4 transcription factor and MMP13 metalloprotease are interplaying actors of breast tumorigenesis.

Dumortier M, Ladam F, Damour I, Vacher S, Bièche I, Marchand N, de Launoit Y, Tulasne D, Chotteau-Lelièvre A.

Breast Cancer Res. 2018 Jul 11;20(1):73. doi: 10.1186/s13058-018-0992-0.

7.

Correction: Protein biomarkers predictive for response to anti-EGFR treatment in RAS wild-type metastatic colorectal carcinoma.

Lièvre A, Ouine B, Canet J, Cartier A, Amar Y, Cacheux W, Mariani O, Guimbaud R, Selves J, Lecomte T, Guyetant S, Bieche I, Berger F, de Koning L.

Br J Cancer. 2018 Jun 14. doi: 10.1038/s41416-018-0130-x. [Epub ahead of print]

PMID:
29899390
8.

Modulation of Rb phosphorylation and antiproliferative response to palbociclib. The Preoperative-Palbociclib (POP) randomized Clinical Trial.

Arnedos M, Bayar MA, Cheaib B, Scott V, Bouakka I, Valent A, Adam J, Leroux-Kozal V, Marty V, Rapinat A, Mazouni C, Sarfati B, Bieche I, Balleyguier C, Gentien D, Delaloge S, Lacroix-Triki M, Michiels S, Andre F.

Ann Oncol. 2018 Jun 11. doi: 10.1093/annonc/mdy202. [Epub ahead of print]

PMID:
29893769
9.

The iron chelator deferasirox synergises with chemotherapy to treat triple-negative breast cancers.

Tury S, Assayag F, Bonin F, Chateau-Joubert S, Servely JL, Vacher S, Becette V, Caly M, Rapinat A, Gentien D, de la Grange P, Schnitzler A, Lallemand F, Marangoni E, Bièche I, Callens C.

J Pathol. 2018 Jun 7. doi: 10.1002/path.5104. [Epub ahead of print]

PMID:
29876931
10.

The trimeric coiled-coil HSBP1 protein promotes WASH complex assembly at centrosomes.

Visweshwaran SP, Thomason PA, Guerois R, Vacher S, Denisov EV, Tashireva LA, Lomakina ME, Lazennec-Schurdevin C, Lakisic G, Lilla S, Molinie N, Henriot V, Mechulam Y, Alexandrova AY, Cherdyntseva NV, Bièche I, Schmitt E, Insall RH, Gautreau A.

EMBO J. 2018 Jul 2;37(13). pii: e97706. doi: 10.15252/embj.201797706. Epub 2018 May 29.

PMID:
29844016
11.

Array comparative genomic hybridization identifies high level of PI3K/Akt/mTOR pathway alterations in anal cancer recurrences.

Cacheux W, Tsantoulis P, Briaux A, Vacher S, Mariani P, Richard-Molard M, Buecher B, Richon S, Jeannot E, Lazartigues J, Rouleau E, Mariani O, El Alam E, Cros J, Roman-Roman S, Mitry E, Girard E, Dangles-Marie V, Lièvre A, Bièche I.

Cancer Med. 2018 May 26. doi: 10.1002/cam4.1533. [Epub ahead of print]

12.

PKD1 is a potential biomarker and therapeutic target in triple-negative breast cancer.

Spasojevic C, Marangoni E, Vacher S, Assayag F, Meseure D, Château-Joubert S, Humbert M, Karam M, Ricort JM, Auclair C, Regairaz M, Bièche I.

Oncotarget. 2018 May 1;9(33):23208-23219. doi: 10.18632/oncotarget.25292. eCollection 2018 May 1.

13.

First French Pilot Quality Assessment of the EndoPredict Test for Early Luminal Breast Carcinoma.

Lehmann-Che J, Miquel C, Wong J, Callens C, Rouleau E, Quillien V, Lozano N, Cayre A, Lacroix L, Bieche I, Bertheau P, Teixeira L, Llorca FP, Lamy PJ, DE Cremoux P; GFCO GROUP.

Anticancer Res. 2018 May;38(5):2909-2914.

PMID:
29715116
14.

Morphology and genomic hallmarks of breast tumours developed by ATM deleterious variant carriers.

Renault AL, Mebirouk N, Fuhrmann L, Bataillon G, Cavaciuti E, Le Gal D, Girard E, Popova T, La Rosa P, Beauvallet J, Eon-Marchais S, Dondon MG, d'Enghien CD, Laugé A, Chemlali W, Raynal V, Labbé M, Bièche I, Baulande S, Bay JO, Berthet P, Caron O, Buecher B, Faivre L, Fresnay M, Gauthier-Villars M, Gesta P, Janin N, Lejeune S, Maugard C, Moutton S, Venat-Bouvet L, Zattara H, Fricker JP, Gladieff L, Coupier I; CoF-AT; GENESIS; kConFab, Chenevix-Trench G, Hall J, Vincent-Salomon A, Stoppa-Lyonnet D, Andrieu N, Lesueur F.

Breast Cancer Res. 2018 Apr 17;20(1):28. doi: 10.1186/s13058-018-0951-9.

15.

Relevance of a molecular tumour board (MTB) for patients' enrolment in clinical trials: experience of the Institut Curie.

Basse C, Morel C, Alt M, Sablin MP, Franck C, Pierron G, Callens C, Melaabi S, Masliah-Planchon J, Bataillon G, Gardrat S, Lavigne M, Bonsang B, Vaflard P, Pons Tostivint E, Dubot C, Loirat D, Marous M, Geiss R, Clément N, Schleiermacher G, Kamoun C, Girard E, Ardin M, Benoist C, Bernard V, Mariani O, Rouzier R, Tresca P, Servois V, Vincent-Salomon A, Bieche I, Le Tourneau C, Kamal M.

ESMO Open. 2018 Apr 6;3(3):e000339. doi: 10.1136/esmoopen-2018-000339. eCollection 2018.

16.

High rate of PIK3CA mutations but no TP53 mutations in low-grade adenosquamous carcinoma of the breast.

Bataillon G, Fuhrmann L, Girard E, Menet E, Laé M, Capovilla M, Treilleux I, Arnould L, Penault-Llorca F, Rouzier R, Marchiò C, Bieche I, Vincent-Salomon A.

Histopathology. 2018 Aug;73(2):273-283. doi: 10.1111/his.13514. Epub 2018 May 7.

PMID:
29537649
17.

COX2/PTGS2 Expression Is Predictive of Response to Neoadjuvant Celecoxib in HER2-negative Breast Cancer Patients.

DE Cremoux P, Hamy AS, Lehmann-Che J, Scott V, Sigal B, Mathieu MC, Bertheau P, Guinebretière JM, Pierga JY, Giacchetti S, Brain E, Marty M, Asselain B, Spyratos F, Bièche I.

Anticancer Res. 2018 Mar;38(3):1485-1490.

PMID:
29491076
18.

Involvement of the FOXO6 transcriptional factor in breast carcinogenesis.

Lallemand F, Petitalot A, Vacher S, de Koning L, Taouis K, Lopez BS, Zinn-Justin S, Dalla-Venezia N, Chemlali W, Schnitzler A, Lidereau R, Bieche I, Caputo SM.

Oncotarget. 2017 Dec 30;9(7):7464-7475. doi: 10.18632/oncotarget.23779. eCollection 2018 Jan 26.

19.

Tumor PIK3CA Genotype and Prognosis in Early-Stage Breast Cancer: A Pooled Analysis of Individual Patient Data.

Zardavas D, Te Marvelde L, Milne RL, Fumagalli D, Fountzilas G, Kotoula V, Razis E, Papaxoinis G, Joensuu H, Moynahan ME, Hennessy BT, Bieche I, Saal LH, Stal O, Iacopetta B, Jensen JD, O'Toole S, Lopez-Knowles E, Barbaraeschi M, Noguchi S, Azim HA Jr, Lerma E, Bachelot T, Wang Q, Perez-Tenorio G, Can de Velde CJH, Rea DW, Sabine V, Bartlett JMS, Sotiriou C, Michiels S, Loi S.

J Clin Oncol. 2018 Apr 1;36(10):981-990. doi: 10.1200/JCO.2017.74.8301. Epub 2018 Feb 22.

PMID:
29470143
20.

Revisited analysis of a SHIVA01 trial cohort using functional mutational analyses successfully predicted treatment outcome.

Kamal M, Tarcic G, Dureau S, Edelheit O, Barbash Z, Lecerf C, Morel C, Miron B, Callens C, Servant N, Bieche I, Vidne M, Le Tourneau C.

Mol Oncol. 2018 May;12(5):594-601. doi: 10.1002/1878-0261.12180. Epub 2018 Mar 30.

21.

Capecitabine Efficacy Is Correlated with TYMP and RB1 Expression in PDX Established from Triple-Negative Breast Cancers.

Marangoni E, Laurent C, Coussy F, El-Botty R, Château-Joubert S, Servely JL, de Plater L, Assayag F, Dahmani A, Montaudon E, Nemati F, Fleury J, Vacher S, Gentien D, Rapinat A, Foidart P, Sounni NE, Noel A, Vincent-Salomon A, Lae M, Decaudin D, Roman-Roman S, Bièche I, Piccart M, Reyal F.

Clin Cancer Res. 2018 Jun 1;24(11):2605-2615. doi: 10.1158/1078-0432.CCR-17-3490. Epub 2018 Feb 20.

PMID:
29463559
22.

Exome sequencing reveals aberrant signalling pathways as hallmark of treatment-naive anal squamous cell carcinoma.

Cacheux W, Dangles-Marie V, Rouleau E, Lazartigues J, Girard E, Briaux A, Mariani P, Richon S, Vacher S, Buecher B, Richard-Molard M, Jeannot E, Servant N, Farkhondeh F, Mariani O, Rio-Frio T, Roman-Roman S, Mitry E, Bieche I, Lièvre A.

Oncotarget. 2017 Dec 8;9(1):464-476. doi: 10.18632/oncotarget.23066. eCollection 2018 Jan 2.

23.

Involvement of Aryl hydrocarbon receptor in myelination and in human nerve sheath tumorigenesis.

Shackleford G, Sampathkumar NK, Hichor M, Weill L, Meffre D, Juricek L, Laurendeau I, Chevallier A, Ortonne N, Larousserie F, Herbin M, Bièche I, Coumoul X, Beraneck M, Baulieu EE, Charbonnier F, Pasmant E, Massaad C.

Proc Natl Acad Sci U S A. 2018 Feb 6;115(6):E1319-E1328. doi: 10.1073/pnas.1715999115. Epub 2018 Jan 19.

24.

Comprehensive genomic profiling of head and neck squamous cell carcinoma reveals FGFR1 amplifications and tumour genomic alterations burden as prognostic biomarkers of survival.

Dubot C, Bernard V, Sablin MP, Vacher S, Chemlali W, Schnitzler A, Pierron G, Ait Rais K, Bessoltane N, Jeannot E, Klijanienko J, Mariani O, Jouffroy T, Calugaru V, Hoffmann C, Lesnik M, Badois N, Berger F, Le Tourneau C, Kamal M, Bieche I.

Eur J Cancer. 2018 Mar;91:47-55. doi: 10.1016/j.ejca.2017.12.016. Epub 2018 Jan 11.

PMID:
29331751
25.

High AHR expression in breast tumors correlates with expression of genes from several signaling pathways namely inflammation and endogenous tryptophan metabolism.

Vacher S, Castagnet P, Chemlali W, Lallemand F, Meseure D, Pocard M, Bieche I, Perrot-Applanat M.

PLoS One. 2018 Jan 10;13(1):e0190619. doi: 10.1371/journal.pone.0190619. eCollection 2018.

26.

Assessment of the functional impact of germline BRCA1/2 variants located in non-coding regions in families with breast and/or ovarian cancer predisposition.

Dos Santos ES, Caputo SM, Castera L, Gendrot M, Briaux A, Breault M, Krieger S, Rogan PK, Mucaki EJ, Burke LJ; ENIGMA consortium, Bièche I, Houdayer C, Vaur D, Stoppa-Lyonnet D, Brown MA, Lallemand F, Rouleau E.

Breast Cancer Res Treat. 2018 Apr;168(2):311-325. doi: 10.1007/s10549-017-4602-0. Epub 2017 Dec 13.

PMID:
29236234
27.

Changes in chromatin state reveal ARNT2 at a node of a tumorigenic transcription factor signature driving glioblastoma cell aggressiveness.

Bogeas A, Morvan-Dubois G, El-Habr EA, Lejeune FX, Defrance M, Narayanan A, Kuranda K, Burel-Vandenbos F, Sayd S, Delaunay V, Dubois LG, Parrinello H, Rialle S, Fabrega S, Idbaih A, Haiech J, Bièche I, Virolle T, Goodhardt M, Chneiweiss H, Junier MP.

Acta Neuropathol. 2018 Feb;135(2):267-283. doi: 10.1007/s00401-017-1783-x. Epub 2017 Nov 17.

28.

mRNA Expression levels of genes involved in antitumor immunity: Identification of a 3-gene signature associated with prognosis of muscle-invasive bladder cancer.

Le Goux C, Vacher S, Pignot G, Sibony M, Barry Delongchamps N, Terris B, Piaggio E, Zerbib M, Damotte D, Bieche I.

Oncoimmunology. 2017 Aug 14;6(11):e1358330. doi: 10.1080/2162402X.2017.1358330. eCollection 2017.

29.

Protein biomarkers predictive for response to anti-EGFR treatment in RAS wild-type metastatic colorectal carcinoma.

Lièvre A, Ouine B, Canet J, Cartier A, Amar Y, Cacheux W, Mariani O, Guimbaud R, Selves J, Lecomte T, Guyetant S, Bieche I, Berger F, de Koning L.

Br J Cancer. 2017 Dec 5;117(12):1819-1827. doi: 10.1038/bjc.2017.353. Epub 2017 Oct 12. Erratum in: Br J Cancer. 2018 Jun 14;:.

30.

Comprehensive clinical and molecular analyses of neuroendocrine carcinomas of the breast.

Lavigne M, Menet E, Tille JC, Lae M, Fuhrmann L, Bonneau C, Deniziaut G, Melaabi S, Ng CCK, Marchiò C, Rouzier R, Bièche I, Vincent-Salomon A.

Mod Pathol. 2018 Jan;31(1):68-82. doi: 10.1038/modpathol.2017.107. Epub 2017 Sep 8.

PMID:
28884749
31.

Neuronal Cholesterol Accumulation Induced by Cyp46a1 Down-Regulation in Mouse Hippocampus Disrupts Brain Lipid Homeostasis.

Ayciriex S, Djelti F, Alves S, Regazzetti A, Gaudin M, Varin J, Langui D, Bièche I, Hudry E, Dargère D, Aubourg P, Auzeil N, Laprévote O, Cartier N.

Front Mol Neurosci. 2017 Jul 11;10:211. doi: 10.3389/fnmol.2017.00211. eCollection 2017.

32.

Tubulin glycylation controls primary cilia length.

Gadadhar S, Dadi H, Bodakuntla S, Schnitzler A, Bièche I, Rusconi F, Janke C.

J Cell Biol. 2017 Sep 4;216(9):2701-2713. doi: 10.1083/jcb.201612050. Epub 2017 Jul 7.

33.

HPV circulating tumor DNA to monitor the efficacy of anti-PD-1 therapy in metastatic squamous cell carcinoma of the anal canal: A case report.

Cabel L, Bidard FC, Servois V, Cacheux W, Mariani P, Romano E, Minsat M, Bieche I, Farkhondeh F, Jeannot E, Buecher B.

Int J Cancer. 2017 Oct 15;141(8):1667-1670. doi: 10.1002/ijc.30863. Epub 2017 Jul 12.

PMID:
28670746
34.

Inactivation of the Kinase Domain of CDK10 Prevents Tumor Growth in a Preclinical Model of Colorectal Cancer, and Is Accompanied by Downregulation of Bcl-2.

Weiswald LB, Hasan MR, Wong JCT, Pasiliao CC, Rahman M, Ren J, Yin Y, Gusscott S, Vacher S, Weng AP, Kennecke HF, Bièche I, Schaeffer DF, Yapp DT, Tai IT.

Mol Cancer Ther. 2017 Oct;16(10):2292-2303. doi: 10.1158/1535-7163.MCT-16-0666. Epub 2017 Jun 29.

PMID:
28663269
35.

The SHIVA01 trial: what have we learned?

Le Tourneau C, Kamal M, Bièche I.

Pharmacogenomics. 2017 Jun;18(9):831-834. doi: 10.2217/pgs-2017-0062. Epub 2017 Jun 8. No abstract available.

36.

Clinical value of R-spondins in triple-negative and metaplastic breast cancers.

Coussy F, Lallemand F, Vacher S, Schnitzler A, Chemlali W, Caly M, Nicolas A, Richon S, Meseure D, El Botty R, De-Plater L, Fuhrmann L, Dubois T, Roman-Roman S, Dangles-Marie V, Marangoni E, Bièche I.

Br J Cancer. 2017 Jun 6;116(12):1595-1603. doi: 10.1038/bjc.2017.131. Epub 2017 May 4.

37.

Circulating tumor DNA changes for early monitoring of anti-PD1 immunotherapy: a proof-of-concept study.

Cabel L, Riva F, Servois V, Livartowski A, Daniel C, Rampanou A, Lantz O, Romano E, Milder M, Buecher B, Piperno-Neumann S, Bernard V, Baulande S, Bieche I, Pierga JY, Proudhon C, Bidard FC.

Ann Oncol. 2017 Aug 1;28(8):1996-2001. doi: 10.1093/annonc/mdx212.

PMID:
28459943
38.

Baseline β-catenin, programmed death-ligand 1 expression and tumour-infiltrating lymphocytes predict response and poor prognosis in BRAF inhibitor-treated melanoma patients.

Massi D, Romano E, Rulli E, Merelli B, Nassini R, De Logu F, Bieche I, Baroni G, Cattaneo L, Xue G, Mandalà M.

Eur J Cancer. 2017 Jun;78:70-81. doi: 10.1016/j.ejca.2017.03.012. Epub 2017 Apr 14.

PMID:
28412591
39.

Correlation between messenger RNA expression and protein expression of immune checkpoint-associated molecules in bladder urothelial carcinoma: A retrospective study.

Le Goux C, Damotte D, Vacher S, Sibony M, Delongchamps NB, Schnitzler A, Terris B, Zerbib M, Bieche I, Pignot G.

Urol Oncol. 2017 May;35(5):257-263. doi: 10.1016/j.urolonc.2017.01.014. Epub 2017 Mar 11.

PMID:
28291636
40.

Metabolic Response to Everolimus in Patient-Derived Triple-Negative Breast Cancer Xenografts.

Euceda LR, Hill DK, Stokke E, Hatem R, El Botty R, Bièche I, Marangoni E, Bathen TF, Moestue SA.

J Proteome Res. 2017 May 5;16(5):1868-1879. doi: 10.1021/acs.jproteome.6b00918. Epub 2017 Apr 3.

PMID:
28290700
41.

The critical role of the ZNF217 oncogene in promoting breast cancer metastasis to the bone.

Bellanger A, Donini CF, Vendrell JA, Lavaud J, Machuca-Gayet I, Ruel M, Vollaire J, Grisard E, Győrffy B, Bièche I, Peyruchaud O, Coll JL, Treilleux I, Maguer-Satta V, Josserand V, Cohen PA.

J Pathol. 2017 May;242(1):73-89. doi: 10.1002/path.4882. Epub 2017 Mar 27.

PMID:
28207159
42.

Circulating tumor cells and circulating tumor DNA: What surgical oncologists need to know?

Cabel L, Proudhon C, Mariani P, Tzanis D, Beinse G, Bieche I, Pierga JY, Bidard FC.

Eur J Surg Oncol. 2017 May;43(5):949-962. doi: 10.1016/j.ejso.2017.01.010. Epub 2017 Jan 29. Review.

PMID:
28185687
43.

Alterations in the balance of tubulin glycylation and glutamylation in photoreceptors leads to retinal degeneration.

Bosch Grau M, Masson C, Gadadhar S, Rocha C, Tort O, Marques Sousa P, Vacher S, Bieche I, Janke C.

J Cell Sci. 2017 Mar 1;130(5):938-949. doi: 10.1242/jcs.199091. Epub 2017 Jan 19.

44.

Feasibility and clinical integration of molecular profiling for target identification in pediatric solid tumors.

Pincez T, Clément N, Lapouble E, Pierron G, Kamal M, Bieche I, Bernard V, Fréneaux P, Michon J, Orbach D, Aerts I, Pacquement H, Bourdeaut F, Jiménez I, Thébaud E, Oudot C, Vérité C, Taque S, Owens C, Doz F, Le Tourneau C, Delattre O, Schleiermacher G.

Pediatr Blood Cancer. 2017 Jun;64(6). doi: 10.1002/pbc.26365. Epub 2016 Nov 29.

PMID:
27896933
45.

Combination of COX-2 expression and PIK3CA mutation as prognostic and predictive markers for celecoxib treatment in breast cancer.

Tury S, Becette V, Assayag F, Vacher S, Benoist C, Kamal M, Marangoni E, Bièche I, Lerebours F, Callens C.

Oncotarget. 2016 Dec 20;7(51):85124-85141. doi: 10.18632/oncotarget.13200.

46.

Gain-of-function Prolactin Receptor Variants Are Not Associated With Breast Cancer and Multiple Fibroadenoma Risk.

Chakhtoura Z, Laki F, Bernadet M, Cherifi I, Chiche A, Pigat N, Bernichtein S, Courtillot C, Boutillon F, Bièche I, Vacher S, Tanguy ML, Bissery A, Grouthier V, Camparo P, Foretz M, Do Cruzeiro M, Pierre R, Rakotozafy F, Tichet J, Tejedor I, Guidotti JE, Sigal-Zafrani B, Goffin V, Touraine P.

J Clin Endocrinol Metab. 2016 Nov;101(11):4449-4460. Epub 2016 Aug 30.

PMID:
27575941
47.

MED12 mutations in breast phyllodes tumors: evidence of temporal tumoral heterogeneity and identification of associated critical signaling pathways.

Laé M, Gardrat S, Rondeau S, Richardot C, Caly M, Chemlali W, Vacher S, Couturier J, Mariani O, Terrier P, Bièche I.

Oncotarget. 2016 Dec 20;7(51):84428-84438. doi: 10.18632/oncotarget.12991.

48.

MicroRNA-based diagnostic tools for advanced fibrosis and cirrhosis in patients with chronic hepatitis B and C.

Appourchaux K, Dokmak S, Resche-Rigon M, Treton X, Lapalus M, Gattolliat CH, Porchet E, Martinot-Peignoux M, Boyer N, Vidaud M, Bedossa P, Marcellin P, Bièche I, Estrabaud E, Asselah T.

Sci Rep. 2016 Oct 12;6:34935. doi: 10.1038/srep34935.

49.

CXCR4 inhibitors could benefit to HER2 but not to triple-negative breast cancer patients.

Lefort S, Thuleau A, Kieffer Y, Sirven P, Bieche I, Marangoni E, Vincent-Salomon A, Mechta-Grigoriou F.

Oncogene. 2017 Mar 2;36(9):1211-1222. doi: 10.1038/onc.2016.284. Epub 2016 Sep 26.

50.

Combination of Carboplatin and Bevacizumab Is an Efficient Therapeutic Approach in Retinoblastoma Patient-Derived Xenografts.

Assayag F, Nicolas A, Vacher S, Dehainault C, Bieche I, Meseure D, Aerts I, Cassoux N, Houdayer C, Doz F, Decaudin D.

Invest Ophthalmol Vis Sci. 2016 Sep 1;57(11):4916-4926. doi: 10.1167/iovs.15-18725.

PMID:
27654418

Supplemental Content

Loading ...
Support Center